// App-Quantinova.ai

324 : Long-term outcomes and predictive factors in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) showing abiraterone withdrawal syndrome (AWS) after docetaxel (DOC) treatment.

Researchers

Presenter

  • Orazio Caffo

Principal Investigators

  • Francesca Maines

  • Chiara Trentin

  • Antonello Veccia

  • Enzo Galligioni

Medical Centers

  • Santa Chiara Hospital, Trento, Italy

  • Medical Oncology Santa Chiara Hospital, Trento, Italy

Locations

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Prostate specific antigen

Drug/Treatment

  • CB-7598

  • Prednisone

  • Docetaxel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved